Literature DB >> 12173120

General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.

Ellie J C Goldstein1, Diane M Citron, C Vreni Merriam, Yumi Warren, Kerin L Tyrrell, Richard M Gesser.   

Abstract

In a recently completed study of once-a-day ertapenem versus piperacillin-tazobactam every 6 h in the treatment of complicated skin and skin-structure infections, 540 patients were randomized in a 1rcolon;1 ratio and assigned to 1 of 2 strata: those with a complicating underlying disease or all others. The most common infections in the study were deep soft-tissue abscess (18.9%), followed by diabetic lower extremity infection (18.1%); 7.0% of these were perineal cellulitis/abscess. With the exception of methicillin-resistant Staphylococcus aureus, almost all of the predominant aerobic pathogens were susceptible to both study drugs. Eighty-seven patients (16%) had >/=1 anaerobe identified in their baseline wound cultures, with a total of 232 anaerobic isolates. Of the 141 anaerobes tested for susceptibility, 97.2% were susceptible to ertapenem and 97.9% to piperacillin-tazobactam. Ertapenem had excellent in vitro activity against the most common aerobic pathogens and almost all anaerobes recovered from patients with infections of the skin and skin structures.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173120     DOI: 10.1086/341932

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

Review 1.  Ertapenem: a review of its use in the treatment of bacterial infections.

Authors:  Gillian M Keating; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Ertapenem: a review of its use in the management of bacterial infections.

Authors:  Monique Curran; Dene Simpson; Caroline Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.

Authors:  D M Citron; K L Tyrrell; C V Merriam; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2010-01-25       Impact factor: 5.191

5.  Ceftaroline in complicated skin and skin-structure infections.

Authors:  Paul O Hernandez; Sergio Lema; Stephen K Tyring; Natalia Mendoza
Journal:  Infect Drug Resist       Date:  2012-01-19       Impact factor: 4.003

6.  Community analysis of chronic wound bacteria using 16S rRNA gene-based pyrosequencing: impact of diabetes and antibiotics on chronic wound microbiota.

Authors:  Lance B Price; Cindy M Liu; Johan H Melendez; Yelena M Frankel; David Engelthaler; Maliha Aziz; Jolene Bowers; Rogan Rattray; Jacques Ravel; Chris Kingsley; Paul S Keim; Gerald S Lazarus; Jonathan M Zenilman
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

7.  Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.

Authors:  Sai-Cheong Lee; Shie-Shian Huang; Chao-Wei Lee; Chang-Phone Fung; Ning Lee; Wen-Bin Shieh; L K Siu
Journal:  BMC Infect Dis       Date:  2007-07-17       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.